VYNE VYNE Therapeutics
- 2.5300
- -0.0601-2.32%
- 2.5000
- -0.0300-1.19%
VYNE Therapeutics News
Buy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline Progression
Analysts' Top Healthcare Picks: VYNE Therapeutics (VYNE), TriSalus Life Sciences (TLSI)
VYNE Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
Buy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical Pipeline
VYNE Therapeutics Analyst Ratings
Buy Rating Affirmed for VYNE Therapeutics on Promising Drug Development Milestones and Positive Clinical Data
Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments
VYNE Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)
Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results
Buy Rating Assigned to VYNE Therapeutics Based on Promising Progress of Primary Assets VYN201 and VYN202 for Inflammatory Conditions
HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $5.75
VYNE Therapeutics Analyst Ratings
Promising Phase 1b Trial Results Bolster Buy Rating for VYNE Therapeutics: An Examination of VYN201's Potential in Vitiligo Treatment
Analysts Conflicted on These Healthcare Names: Gritstone Oncology (GRTS) and VYNE Therapeutics (VYNE)
VYNE Therapeutics Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating
Cantor Fitzgerald Maintains Overweight on VYNE Therapeutics, Raises Price Target to $9
HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $28 Price Target
Analysis
Price Target
No Data
